TrialReader


Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

NCT03235141 — Phase 1, Unknown, 56 participants, Beijing Tongren Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03235141
StatusUnknown
PhasePhase 1
Study typeInterventional; randomized, crossover, masking: double, treatment
Enrollment56 (Estimated)
SponsorBeijing Tongren Hospital (Other); collaborators: Zhuhai Essex Bio-Pharmaceutical Company Limited, Panacea Technologies
ConditionsBacterial Conjunctivitis
Interventionsazithromycin eye drops by essex, azithromycin eye drops (Drug)
Datesstart 2017-07-07, primary completion 2017-10-30 (estimated), completion 2017-12-30 (estimated), first posted 2017-08-01, last updated 2017-08-01
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Bacterial Conjunctivitis All trials of azithromycin eye drops by essex All trials of azithromycin eye drops

-Summary

To compare the pharmacokinetic behavior of azithromycin eye drops in the tear with the original azithromycin eye drops, and evaluate the release behavior of both in the eye.

Expand all sections  ·  Collapse all

+Detailed description

There are 48 patients will divided into group A and group B randomly . subjects of Group A will given the first test drug, elution after the control drug; Subjects of Group B will given the first control drug, elution given to the test drug.

+Arms and interventions

ArmTypeInterventionsDescription
azithromycin eye drops by essexExperimentalDrug: azithromycin eye drops by essex; Drug: azithromycin eye dropsIn one cycle, give the azithromycin eye drops by essex,2.5ml/25mg,1 drop,once. In the second cycle(after 14 days elution),give the AzaSite eye drops,2.5ml/25mg,1 drop,once.
AzaSiteActive comparatorDrug: azithromycin eye drops by essex; Drug: azithromycin eye dropsIn one cycle, give the AzaSite eye drops,2.5ml/25mg,1 drop,once. In the second cycle(after 14 days elution),give the azithromycin eye drops by essex,2.5ml/25mg,1 drop,once.
  • azithromycin eye drops by essex (Drug): azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
  • azithromycin eye drops (Drug), also known as AzaSite: azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc

+Outcome measures

Primary outcomes

  • AUC0-t [The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours]: The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours,The AUC of the test drug and the control drug was calculated at the average concentration of each point

Secondary outcomes

  • Cmax [The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours]: The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours,The Cmax of the test drug and the control drug was calculated at the average concentration of each point
  • AE [from the ICF signed to the end of the trial,through study completion, an average of 1 year]: compared the laboratory test values before and after treatment,according to the study drug use, calculate the number of cases, the number of cases and the incidence of adverse reactions.
  • SAE [from the ICF signed to the end of the trial,through study completion, an average of 1 year]: Any serious adverse events that occur during the clinical study, whether or not related to the drug should be collected.

+Eligibility

Sex: All, ages: 18 Years to 65 Years, accepts healthy volunteers

Inclusion Criteria:

* 18 to 65 years old, male or female;
* BMI in the range of 19 to 28;
* eyes corrected visual acuity should be ≥ 1.0, intraocular pressure, slit lamp and fundus examination were normal, tear secretion function is normal;
* Good compliance and voluntarily signed consent.

Exclusion Criteria:

* Have eye disease or systemic disease;
* physical examination, laboratory tests, ECG and chest X-ray examination abnormalities and has clinical significance;
* HBsAg, anti-HCV and HIV positive;
* those who used eye drops two weeks before the test and who used any dosage form of azithromycin;
* known to azithromycin or macrolide-related varieties of allergies or serious adverse reactions;
* need to wear contact lenses during the test;
* history of internal surgery or laser surgery history;
* participated in other drug clinical trials in the past three months;
* pregnant women and lactating women, or in the growth period without taking effective contraceptive measures, menstrual period women;
* mental illness or alcohol, history of drug abuse or inability to collaborate;
* Any other circumstances that the investigators consider are unfit to participate in this study.

+Locations (1)

FacilityCityCountryStatus
Beijing Tongren HospitalBeijing, Beijing MunicipalityChinaRecruiting

+Investigators

  • Xiuli Zhao, Principal investigator, Beijing Tongren Hospital

My Notes